Curocell

Curocell Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Curocell (372320.KQ) as of Nov 4, 2026 is 64.77 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 74.33 % — a change of -12.85% (lower).

Cash Conversion

64.77 %

YoY

-12.85%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Curocell is 2025 64.77 % . Cash Conversion Rate (OCF/Net Income) of Curocell was 2024 74.33 % . It decreases by -12.85% lower compared to the previous year.

The Curocell Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2021
21.53 KRW
Jan 1, 2022
37.01 KRW
Jan 1, 2023
85.42 KRW
Jan 1, 2024
74.33 KRW
Jan 1, 2025
64.77 KRW
The Curocell Cash Conversion history
YEARCash ConversionYoY
64.77 %-12.85%
74.33 %-12.99%
85.42 %+130.80%
37.01 %+71.89%
21.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Cash Conversion Rate (OCF/Net Income) of Curocell is 64.77 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Curocell changed from 74.33 % to 64.77 %, representing a -12.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Curocell since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Curocell with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curocell

All Key Metrics — Curocell